Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
262 results:
1. [Genetic drivers for inflammatory protein markers in colorectal cancer: a Mendelian randomization approach to clinical prognosis study].
Li H; Li G; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jul; 44(7):1361-1369. PubMed ID: 39051082
[TBL] [Abstract] [Full Text] [Related]
2. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis.
Yu H; Liu Q; Wu K; Tang S
Clin Exp Med; 2024 Jul; 24(1):143. PubMed ID: 38960935
[TBL] [Abstract] [Full Text] [Related]
3. Tumor-infiltrating lymphocytes, pd-l1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
[TBL] [Abstract] [Full Text] [Related]
5. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
[TBL] [Abstract] [Full Text] [Related]
6. Development of an anoikis-related gene signature and prognostic model for predicting the tumor microenvironment and response to immunotherapy in colorectal cancer.
Li C; Weng J; Yang L; Gong H; Liu Z
Front Immunol; 2024; 15():1378305. PubMed ID: 38779664
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of pd-l1 expression in patients with anal cancer: a meta-analysis.
Gong S; Song J
Biomark Med; 2024; 18(7):333-344. PubMed ID: 38700275
[TBL] [Abstract] [Full Text] [Related]
8. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
9. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and pd-l1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract] [Full Text] [Related]
10. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic colorectal cancer.
Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
13. pd-l1 Expression in colorectal Carcinoma Correlates with the Immune Microenvironment.
Shahin M; Patra S; Purkait S; Kar M; Das Majumdar SK; Mishra TS; Samal SC; Nayak HK
J Gastrointest Cancer; 2024 Jun; 55(2):940-949. PubMed ID: 38530597
[TBL] [Abstract] [Full Text] [Related]
14. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract] [Full Text] [Related]
15. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
16. A comprehensive multi-omics analysis identifies a robust scoring system for cancer-associated fibroblasts and intervention targets in colorectal cancer.
Wang F; Li Z; Xu T; Zhang Q; Ma T; Li S; Wang X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):124. PubMed ID: 38478111
[TBL] [Abstract] [Full Text] [Related]
17. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
[TBL] [Abstract] [Full Text] [Related]
18. TMEM160 promotes tumor immune evasion and radiotherapy resistance via pd-l1 binding in colorectal cancer.
Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
[TBL] [Abstract] [Full Text] [Related]
19. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
[TBL] [Abstract] [Full Text] [Related]
20. colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and pd-l1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
[Next]
